NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 is also an effective anti-tumor agent that displays selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 offers possibilities

NSC745885 (0.5-4 μM; 24 hours) enhances annexin V positive cells in a dose-dependent manner, and the differences appear as a dose-dependent manner. NSC745885 (0.5-2 μM; 24 or 48 hours) reduces XIAP protein levels and increases protein levels both as a dose-dependent manner in SAS cells. NSC745885 (0.5-4 μM; 24, 48 or 72 hours) has a growth inhibitory or death-promoting effect on the SAS cells, it significantly decreases the densities of cultured cells when compared with untreated cells. The IC50 of NSC745885 is 0.85 μM after 72 hours' treatment [1].

NSC745885 (intraperitoneal injection; 2 mg/kg; once daily; 10 days) treatment obviously decreases tumor size when compared with the vehicle control. It shows higher safety than doxorubicin[1].